Augma Biomaterials

About

Q&A

What is Augma Biomaterials' primary focus?

Augma Biomaterials specializes in the development, production, and marketing of synthetic bone substitutes for the dental market.

What are Augma Biomaterials' key products?

Augma Biomaterials offers 3D Bond, a biphasic calcium sulfate scaffold for bone regeneration, and Bond Apatite, a cement-based osteoconductive composite combining 3D Bond with hydroxyapatite granules for bone reconstruction.

What regulatory approvals do Augma Biomaterials' products have?

Augma Biomaterials' Bond Apatite product is FDA cleared and CE approved.

When was Augma Biomaterials founded?

Augma Biomaterials was founded in November 2009.

Where is Augma Biomaterials headquartered?

Augma Biomaterials is headquartered in Caesarea, Israel.

What is the employee count for Augma Biomaterials?

Augma Biomaterials has 11-50 employees.

In which sector does Augma Biomaterials primarily operate?

Augma Biomaterials operates primarily in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.

Does Augma Biomaterials have an office in the United States?

Yes, Augma Biomaterials has an office in Monroe Township, New Jersey, USA.

Sectors & technology

Tags